Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 9

Change from baseline in serum creatinine over the 24-week follow-up period in the CKD stage3b subgroup.

Time	Treatment group	Control group	Effect	F value	value
Pretreatment (μmol/L)	165.75 ± 40.14	162.38 ± 27.96	Time effect	2.34	0.0403
Week 4 (μmol/L)	156.07 ± 31.57	163.22 ± 38.99	Difference between groups	25.53	<0.0001
Week 8 (μmol/L)	148.40 ± 31.59	164.48 ± 40.41
Week 12 (μmol/L)	147.72 ± 31.77	162.95 ± 37.74
Week 16 (μmol/L)	144.15 ± 30.74	166.01 ± 37.26
Week 20 (μmol/L)	143.73 ± 32.26	167.48 ± 36.37
Week 24 (μmol/L)	145.46 ± 34.02	163.64 ± 40.71